These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7076369)

  • 1. Initial methadone dose in treating opiate addiction.
    Wang RI; Kochar C; Hasegawa AT; Roh BL
    Int J Addict; 1982 Feb; 17(2):357-63. PubMed ID: 7076369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.
    Stine SM; Kosten TR
    Am J Drug Alcohol Abuse; 1994 Nov; 20(4):445-58. PubMed ID: 7832179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
    Stitzer ML; Wright C; Bigelow GE; June HL; Felch LJ
    Drug Alcohol Depend; 1991 Dec; 29(1):39-46. PubMed ID: 1665778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT).
    Krystal JH; Woods SW; Kosten TR; Rosen MI; Seibyl JP; van Dyck CC; Price LH; Zubal IG; Hoffer PB; Charney DS
    Am J Drug Alcohol Abuse; 1995 Feb; 21(1):47-63. PubMed ID: 7762544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new rating scales for opiate withdrawal.
    Handelsman L; Cochrane KJ; Aronson MJ; Ness R; Rubinstein KJ; Kanof PD
    Am J Drug Alcohol Abuse; 1987; 13(3):293-308. PubMed ID: 3687892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
    de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
    Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial.
    Zarghami M; Masoum B; Shiran MR
    J Addict Dis; 2012; 31(2):112-7. PubMed ID: 22540433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML
    NIDA Res Monogr; 1989; 95():395-6. PubMed ID: 2701308
    [No Abstract]   [Full Text] [Related]  

  • 12. Expanded table: Some drugs for management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):e144-e146. PubMed ID: 30133422
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects.
    Kanof PD; Handelsman L; Aronson MJ; Ness R; Cochrane KJ; Rubinstein KJ
    J Pharmacol Exp Ther; 1992 Jan; 260(1):355-63. PubMed ID: 1731046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.
    Chopra MP; Feldman Z; Mancino MJ; Oliveto A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):787-96. PubMed ID: 18585405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of opioid withdrawal symptoms.
    Med Lett Drugs Ther; 2018 Aug; 60(1554):137-141. PubMed ID: 30133420
    [No Abstract]   [Full Text] [Related]  

  • 16. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial.
    Beswick T; Best D; Bearn J; Gossop M; Rees S; Strang J
    Am J Addict; 2003; 12(4):295-305. PubMed ID: 14504022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
    Kienbaum P; Scherbaum N; Thürauf N; Michel MC; Gastpar M; Peters J
    Crit Care Med; 2000 Apr; 28(4):969-76. PubMed ID: 10809268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The naloxone test for opiate dependence.
    Judson BA; Himmelberger DU; Goldstein A
    Clin Pharmacol Ther; 1980 Apr; 27(4):492-501. PubMed ID: 7357808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.